SABCS 2025
San Antonio Breast Cancer Symposium 2025 | Date: December 9 - 12, 2025 | Venue: Henry B. Gonzalez Convention Center, San Antonio, TX, USA
Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
Additional efficacy and safety from the DESTINY-Breast05 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary early breast cancer with residual invasive disease after neoadjuvant therapy
Sibylle Loibl
Poster
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
DESTINY-Breast Respond HER2-low Europe:
Description of first enrolled patients in the
non-interventional study of T-DXd in HER2-low
metastatic breast cancer
Valentina Guarneri
Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
DESTINY-Breast11 safety: Neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer
Giuseppe Curigliano
Poster
Dato-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
Economic impact of adverse event management in HR+/HER2− metastatic breast cancer: A comparative analysis of datopotamab deruxtecan and standard of care in the Brazilian private healthcare system
Henrique Tortele dos Santos
Poster
Dato-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
First-line datopotamab deruxtecan (Dato-DXd) vs
chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional safety analyses from the TROPION-Breast02 study
Tiffany A. Traina
Poster
HER3-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
HERTHENA-Breast01: A phase 1b/2, multicenter, open-label, dose-finding study to evaluate the safety and antitumor activity of patritumab deruxtecan (HER3-DXd) in human epidermal growth factor receptor 2-positive unresectable locally advanced or metastatic breast cancer
Sara M. Tolaney
Poster
HER3-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan (HER3-DXd) plus pembrolizumab before or after pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer (TNBC) or hormone receptor–low positive (HR-low+)/human epidermal growth factor receptor 2–negative (HER2−) breast cancer
Joyce O’Shaughnessy
Poster
HER3-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) vs treatment of physician’s choice in hormone receptor–positive/human epidermal growth factor receptor 2–negative unresectable locally advanced or metastatic breast cancer
Barbara Pistilli
Poster
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
Interim analysis results for the effectiveness
and safety of trastuzumab deruxtecan in
patients with HER2-low breast cancer and
brain metastases: The HALLOW Study
Naoki Niikura
Poster
T-DXd
SABCS 2025 | December 9 - 12, 2025
Breast Cancer
Interim results from the HER-TEMPO study: Real-world study of treatment discontinuations and modifications for patients with HER2-low metastatic breast cancer on trastuzumab deruxtecan
Christine Brezden-Masley
